BOSTON, Mass. — Tahoe Therapeutics and Alloy Therapeutics said they are forming a jointly seeded new company dedicated to developing first-in-class antibody-drug conjugates for patients with hard-to-treat cancers.
The joint venture will initially advance two ADC programs built on novel tumor targets identified by Tahoe Therapeutics using its proprietary Mosaic platform. Tahoe said the targets were discovered through analysis of large-scale, perturbative single-cell datasets and subsequently validated across multiple independent assays and clinical samples.
The collaboration brings together Tahoe’s AI-powered approach to target discovery with Alloy’s end-to-end capabilities in biologic drug engineering, ADC design, and company creation through its venture studio, 82VS. Alloy said its experience in advancing multiple clinical-stage programs positions the new company to efficiently translate novel biological insights into optimized oncology therapeutics.
“We were immediately impressed by the depth and quality of biological insight generated by the Mosaic platform,” said Errik Anderson, Founder and CEO of Alloy Therapeutics. “With our track record of 20 clinical programs discovered with Alloy platforms and services, including multiple drugs in Phase III, we are well positioned to translate the cutting-edge biology from world-class target-rich companies like Tahoe into optimized therapeutics.”
According to the companies, Tahoe has identified tens of tumor-specific surface antigens from a subset of its multi-million-cell datasets, many of which are novel and were historically difficult to uncover. Following extensive validation, Alloy identified two targets with significant therapeutic potential, leading to the decision to spin out a dedicated ADC-focused company around those programs.
Under the joint venture structure, Tahoe and Alloy will co-invest, co-build, and co-lead the new company. Tahoe will contribute its target discovery and biomarker insights, while Alloy will provide its ADC engineering platforms, translational development expertise, and company-building infrastructure. The partners said the goal is to advance both programs to key value inflection points that could support independent financing or strategic partnerships with pharmaceutical companies.
“Our datasets and AI models are enabling the discovery of novel targets,” said Nima Alidoust, co-founder and CEO of Tahoe Therapeutics. “Alloy, which has had a strong track record in developing first-in-class biologics, shares this excitement with us, and that is a strong validation of the biology discovered by our platform. This joint venture is also a preview of the business model our platform enables: building new companies alongside partners with complementary capabilities.”
The companies said the combined approach is designed to create a more efficient path from target discovery to drug development, with the aim of delivering first-in-class ADC therapies for patients with limited treatment options.
